Pharmaceuticals

ALK released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 340.16 M, actual EPS CNY 0.09

ALK released FY2025 Q4 earnings on April 28 Pre-Market (BJT), actual revenue CNY 369.64 M, actual EPS CNY 0.2255

ALK released FY2025 Annual Earnings on April 28 Pre-Market (BJT), actual revenue CNY 1.425 B, actual EPS CNY 0.62

ALK FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

ALK FY2025 Annual Earnings Release on April 29, 2026 Pre-Market BJT

ALK released FY2025 Q3 earnings on October 24 During-Market (BJT), actual revenue CNY 330.81 M, actual EPS CNY 0.0593

ALK released FY2025 9 Months earnings on October 24 During-Market (BJT), actual revenue CNY 1.055 B, actual EPS CNY 0.3885

ALK to Release FY2025 Q3 Earnings Report on October 25 During-Market BJT

ALK released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 724.35 M, actual EPS CNY 0.33

ALK released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 378.83 M, actual EPS CNY 0.2491

ALK to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Anglican Obtains Pharmaceutical Registration Certificate for Sitagliptin and Metformin Extended-release Tablets

Onlionkang Obtained Pharmaceutical Registration Certificate for Mephenesin Injection

Angliecon Launches New Products to Drive Revenue Growth

Onlionk Introduces Innovation Drug Development Plan

Anlionkang Supervisor Pan Xiaoyun Plans to Sell 159,000 Shares

AngLeeKang Obtains Drug Registration Certificate for Amlodipine Besylate Tablets

Angliecon Hits Limit Up With Record High Price

Onlionk New Concept in Pet Economy

Hunan Kerui Pharmaceutical Passes the GMP Compliance Inspection

159892

516820

159849

002940

Innovative drug concept repeatedly active, ALK straight to the daily limit, Rundu Pharma previously sealed the board, InventisBio, Junshi Biosciences, HWPC, and Biokin Pharmaceutical rose more than 6%

Wallstreetcn

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Rundu Pharma

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

InventisBio

BIOKIN PHARMACEUTICAL

HWPC

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Junshi Biosciences

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

300878

300497

688336

002370

A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

Zhitong

WECOME

Fushine

Sunshine Guojian Pharmaceutical

Yatai pharm

On October 29th, ALK stated during an institutional research that after 2-3 years of high-intensity R&D investment, the company's previously planned generic drug projects have gradually entered the output stage. Starting in 2026, R&D investment related to generic drugs is expected to gradually decrease, with more focus on innovative drug projects

ALK: Starting in 2026, research and development investment will focus more on innovative drug projects

ALK's subsidiary, Animal Health Technology, has obtained the approval number for the veterinary drug product "Amoxicillin Clavulanate Potassium Tablets" from the Ministry of Agriculture and Rural Affairs, with approval numbers 111183373 and 111183374, valid until October 23, 2030. This product is used to treat bacterial infections in dogs and cats, meets the conditions for market sales, will enrich the company's product line, and promote the strategic layout of pet medications, but there is uncertainty regarding its market launch

ALK: Subsidiary obtains approval number for "Amoxicillin Clavulanate Potassium Tablets" veterinary drug product

According to the Zhitong Finance APP, ALK released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. The net profit attributable to shareholders of the listed company was 77.6899 million yuan, a year-on-year increase of 55.59%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 55.7652 million yuan, a year-on-year increase of 39.70%

ALK released its performance for the first three quarters, with a net profit attributable to the parent company of 77.6899 million yuan, a year-on-year increase of 55.59%

002900

The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit, followed by gains in Shutaishen, Asia-Pacific Pharmaceutical, Duoyi Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiya Pharmaceutical

MEDISAN

The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit

ALK announced that its innovative drug project ALK-N001 is currently still in the Phase I clinical trial stage. The company has noted an increase in market attention towards its innovative drug business. On August 26, 2025, ALK signed a strategic cooperation agreement for the ALK-N002 project with Aifang Bio and Qinhuli, and the relevant matters have been approved by the shareholders' meeting. Aifang Bio and Qinhuli are currently undergoing internal approval

ALK: The ALK-N001 project is still in Phase I clinical trials

ALK announced that it recently received the "Drug Registration Certificate" for Levofloxacin Tablets issued by the National Medical Products Administration. Levofloxacin Tablets are a third-generation fluoroquinolone antibacterial drug, characterized by a broad antibacterial spectrum and strong antibacterial effects, used to treat mild, moderate, and severe infections in adults caused by specified sensitive strains. The company received the notice of acceptance for the drug marketing authorization application in April 2024 and has recently been approved

ALK: Obtained the drug registration certificate for Levofloxacin Tablets

002050

The Shanghai Composite Index rose 1.22% to return to 3,900 points, with the overall market strengthening, more stocks rising than falling, and a trading volume of 2.09 trillion. In terms of sectors, robotics, innovative pharmaceuticals, and complete vehicles performed prominently, while shipping ports and agriculture sectors declined. Popular concept stocks such as Sanhua and ALK hit the daily limit, while photolithography concept stocks continued to adjust

Sanhua

The Shanghai Composite Index rose 1.22%, returning to 3,900 points, with nearly 4,400 stocks in the entire market rising

002244

300436

36Kr learned that the three major indices of A-shares collectively rose during the midday break, with the Shanghai Composite Index up 0.1%, the Shenzhen Component Index flat, and the ChiNext Index up 0.22%; the innovative drug concept surged, with Cosunter and ALK hitting the daily limit; the retail and aviation sectors led the gains, with Nanning Department Store rising over 6% and Juneyao Airlines rising over 4%; the basic metals, diversified finance, and real estate sectors weakened, with Western Superconducting and Ganfeng Lithium falling over 6%, China National Petroleum Capital falling over 4%, and Binjiang Group falling over 3%

36Kr

Binjiang Group

Cosunter

The three major A-share indices collectively rose at the midday break, with the innovative drug concept experiencing a surge

ALK(002940.SZ)